May 2026
PTSD
What May 2026's 9 new studies found, synthesized from the papers below. All PTSD research →
The synthesis
Synthesized from 9 studies in the library · AI-generated, grounded in the abstracts below
Found by searching the library for PTSD, post-traumatic stress disorder, traumatic stress, then ranked by relevance.
Research published in May 2026 on PTSD is heterogeneous, spanning pharmacological interventions, neuroimaging, and dream-related predictors. A phase 2 RCT found that the neuroplastogen TSND-201 (methylone) significantly reduced PTSD symptoms versus placebo (CAPS-5 difference of ~9.6 points), while a case study reported benefits from ketamine-assisted psychotherapy. However, other work highlighted reporting errors and hype in psychedelic-assisted therapy research, and a narrative review noted that evidence for intranasal esketamine and psychotherapy combinations remains limited. Overall, findings are promising but preliminary, with small samples and limited long-term data.
Evidence by study
Direction is which way each study's own result points, not our rating of the study.
What the directions mean
- Supports:
- the study found the intervention worked, or its hypothesis held.
- Opposes:
- it found the opposite, no benefit or a harm.
- No effect:
- no significant difference either way.
- Mixed:
- effects in both directions within the same study.
- Unclear:
- the abstract does not report a direction.
| Study | Design | Sample size | Direction | Finding |
|---|---|---|---|---|
| Ketamine-assisted psychotherapy for treatment of an Asian American patient with post-traumatic stress disorder (PTSD): a case study 2026 | case study | 1 | Supports | Ketamine-assisted psychotherapy reduced PTSD symptoms in a 26-year-old Asian American woman with chronic PTSD, with cultural concordance in therapy appearing beneficial. |
| Default mode network resting-state functional connectivity and event centrality in adult acute trauma survivors. 2026 | observational cohort | 215 | Supports | Resting-state functional connectivity between the lateral parietal cortex and hippocampus at 2-4 weeks post-injury was significantly associated with event centrality at 12 months, and adverse psychological outcomes mediated this relationship. |
| Toward Integrating Intranasal Esketamine with Traumatic-Memory Psychotherapy in Treatment-Resistant Depression: A Narrative Review and Feasibility-Oriented Protocol Proposal. 2026 | narrative review | Mixed | The strongest evidence for ketamine in PTSD comes from three randomized trials of intravenous ketamine, while data on intranasal esketamine and psychotherapy combinations are mainly from pilot studies, retrospective analyses, or case reports, and the evidence base remains small, heterogeneous, and largely uncontrolled. | |
| Psychedelic Strawmen: A Call for Greater Transparency of PTSD Treatment Efficacy in Psychedelic-Assisted Therapy Research 2026 | review | Unclear | Argues that reporting errors in psychedelic-assisted therapy research foster inaccurate comparisons with existing PTSD therapies, contributing to hype. | |
| R-MDDMA is a Safer Analogue of MDMA with Therapeutic Potential. 2026 | preclinical study | Supports | R-MDDMA promotes neuroplasticity, fear extinction learning, and antidepressant-like effects without the abuse-related effects of MDMA, suggesting it may be a safer analogue with therapeutic potential. | |
| Efficacy and Safety of the Neuroplastogen TSND-201 for the Treatment of PTSD: A Randomized Clinical Trial. 2026 | randomized controlled trial | 65 | Supports | TSND-201 demonstrated significantly greater improvement in PTSD symptoms than placebo, with a least-squares mean difference of 9.64 points on the CAPS-5 total severity score. |
| 1056 Targeted Dream Incubation’s Impact on Dream Self-Efficacy, Nightmares, Suicide, PTSD, and Insomnia 2026 | controlled trial with two TDI groups and a nap control group | 30 | Mixed | Targeted Dream Incubation increased dream self-efficacy immediately and at one-week follow-up, and in the non-nightmare group it also reduced thoughts of suicide, insomnia, PTSD, and nightmare distress. |
| 0123 Large Language Model-Derived Dream Affect is a Prospective Predictor of PTSD Symptoms in Hospitalized Trauma Patients 2026 | prospective cohort study | 87 | Supports | LLM-derived negative affect and arousal from dreams reported during hospitalization predicted PTSD symptom severity one month later, while self-reported dream affect did not. |
| Longitudinal Outcomes of Oral Glutamatergic Augmentation in Trauma-Related Dissociation: A Six-Month Case Study. 2026 | case study | 1 | Supports | Complete and sustained resolution of dissociative blank-outs and fugue-like states occurred with a dextromethorphan-based glutamatergic regimen. |
Ketamine-assisted psychotherapy reduced PTSD symptoms in a 26-year-old Asian American woman with chronic PTSD, with cultural concordance in therapy appearing beneficial.
case study Sample size: 1
Resting-state functional connectivity between the lateral parietal cortex and hippocampus at 2-4 weeks post-injury was significantly associated with event centrality at 12 months, and adverse psychological outcomes mediated this relationship.
observational cohort Sample size: 215
The strongest evidence for ketamine in PTSD comes from three randomized trials of intravenous ketamine, while data on intranasal esketamine and psychotherapy combinations are mainly from pilot studies, retrospective analyses, or case reports, and the evidence base remains small, heterogeneous, and largely uncontrolled.
narrative review
Argues that reporting errors in psychedelic-assisted therapy research foster inaccurate comparisons with existing PTSD therapies, contributing to hype.
review
R-MDDMA promotes neuroplasticity, fear extinction learning, and antidepressant-like effects without the abuse-related effects of MDMA, suggesting it may be a safer analogue with therapeutic potential.
preclinical study
TSND-201 demonstrated significantly greater improvement in PTSD symptoms than placebo, with a least-squares mean difference of 9.64 points on the CAPS-5 total severity score.
randomized controlled trial Sample size: 65
Targeted Dream Incubation increased dream self-efficacy immediately and at one-week follow-up, and in the non-nightmare group it also reduced thoughts of suicide, insomnia, PTSD, and nightmare distress.
controlled trial with two TDI groups and a nap control group Sample size: 30
LLM-derived negative affect and arousal from dreams reported during hospitalization predicted PTSD symptom severity one month later, while self-reported dream affect did not.
prospective cohort study Sample size: 87
Complete and sustained resolution of dissociative blank-outs and fugue-like states occurred with a dextromethorphan-based glutamatergic regimen.
case study Sample size: 1
Points of agreement
- Several studies suggest that interventions targeting glutamatergic or neuroplastic mechanisms (ketamine, TSND-201, dextromethorphan) may reduce PTSD symptoms.
- Dream-related measures (affect, self-efficacy) appear to be associated with PTSD outcomes.
- There is recognition that the evidence base for psychedelic-assisted therapies in PTSD is still developing and may be subject to hype.
Conflicts
- The narrative review (28768) notes that evidence for intranasal esketamine and psychotherapy combinations is limited, while the case study (36720) reports positive effects of ketamine-assisted psychotherapy, reflecting a discrepancy between anecdotal and controlled evidence.
- The review (37709) argues that reporting errors in PAT research foster inaccurate comparisons, implying that some positive findings may be overstated, whereas the RCT (27909) reports a significant effect for TSND-201.
Gaps
- Long-term durability of treatment effects is not established in most studies.
- Sample sizes are small, especially in case studies and the TDI trial (n=30).
- Blinding and control conditions are lacking in several studies, particularly case studies and the narrative review.
- Populations are limited; for example, the ketamine case study focuses on an Asian American woman, and the RCT excludes certain comorbidities.
- Dose-response relationships and optimal dosing regimens are not fully explored.
- The predictive value of dream affect needs replication in larger, more diverse samples.